Atlas Trials

AK104(PD-1/CTLA-4 Bispecial Antibody)

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch AK104(PD-1/CTLA-4 Bispecial Antibody)

RecordFirmDate
Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer (NCT06542549)Anhui Provincial Hospital2024-10-01

Track AK104(PD-1/CTLA-4 Bispecial Antibody) automatically

Every clearance here is in the API, with alerts when new ones post.